Fact-checked by Grok 2 weeks ago

Factor VII

Factor VII is a vitamin K-dependent serine protease zymogen that initiates the extrinsic pathway of blood coagulation.^[1] Synthesized primarily in the liver as a single-chain glycoprotein with a molecular weight of approximately 50 kDa, Factor VII is encoded by the F7 gene located on the long arm of chromosome 13 (13q34).^[1] The mature protein consists of 406 amino acid residues, featuring a light chain (152 residues) that includes a γ-carboxyglutamic acid (Gla) domain and two epidermal growth factor (EGF)-like domains, linked by a disulfide bond to a heavy chain (254 residues) containing the catalytic serine protease domain with a catalytic triad (His193, Asp219, Ser344).^[1] In plasma, it circulates at concentrations of about 500 ng/mL (0.5 μg/mL, approximately 10 nM), with only 1–2% present in the activated form (FVIIa); its half-life is 2–3 hours.^[1] Upon vascular injury, inactive Factor VII binds to tissue factor (TF), a transmembrane glycoprotein exposed on subendothelial cells and possibly circulating in low amounts, forming the TF-FVIIa complex.^[1] This complex, in a calcium- and phospholipid-dependent manner, activates coagulation factors IX (to IXa) and X (to Xa), with the activation of factor X being the primary step leading to prothrombin conversion to thrombin and subsequent fibrin clot formation.^[1] Activation of Factor VII to FVIIa occurs via limited proteolysis at the Arg152-Ile153 bond, primarily by factor Xa, thrombin, or other proteases, though trace amounts of FVIIa exist constitutively.^[1] The Gla domain is critical for membrane binding, enabling high-affinity interaction with TF and amplifying activity up to 10^6-fold upon complex formation.^[1] Regulation of Factor VII activity involves inhibitors such as tissue factor pathway inhibitor (TFPI), which forms a quaternary complex with TF-FVIIa and factor Xa to quench the initiation phase, and antithrombin, which inactivates FVIIa in the absence of TF.^[1] Plasma levels of Factor VII exhibit significant interindividual variability (up to 4-fold), influenced by genetic polymorphisms in the F7 promoter region, age, sex, and environmental factors like diet and hormones.^[1] Beyond hemostasis, dysregulated TF-FVIIa activity contributes to thrombotic disorders, underscoring its dual role in balancing bleeding and clotting risks.^[1]

Molecular Structure and Genetics

Protein Structure

Factor VII is a vitamin K-dependent glycoprotein that circulates in plasma as a single-chain zymogen with a molecular weight of approximately 50 kDa.^[2] Synthesized in the liver, it exhibits a modular architecture typical of coagulation serine proteases, comprising an N-terminal γ-carboxyglutamic acid (Gla) domain, two epidermal growth factor-like (EGF) domains, and a C-terminal serine protease domain.^[3] The Gla domain (residues 1–38) facilitates binding to calcium ions and phospholipid membranes, while the EGF domains (EGF1: residues 45–85; EGF2: residues 86–152) mediate interactions with cofactors and contribute to structural stability.^[4] The serine protease domain (residues 153–406 in the mature protein) harbors the catalytic machinery essential for its enzymatic activity upon activation.^[5] Post-translational modifications are critical to Factor VII's functionality, including γ-carboxylation of glutamate residues within the Gla domain at positions 6, 7, 14, 16, 19, 20, 25, 26, 29, and 35, which enables high-affinity calcium coordination and membrane association.^[6] Additionally, the protein undergoes N-linked glycosylation at asparagine residues 145 (in EGF2) and 322 (in the protease domain), as well as O-linked glycosylation at serine residues 52 and 60 (in EGF1), which influence folding, secretion, and stability.^[7] These modifications occur in the endoplasmic reticulum and Golgi apparatus, ensuring the zymogen's proper maturation before secretion.^[8] In its zymogen form, Factor VII adopts a conformation where the serine protease domain remains inactive, with the activation site loop partially obstructing the active site.00624-4) Activation to Factor VIIa occurs via proteolytic cleavage at the Arg152-Ile153 bond, generating a light chain (residues 1–152) and heavy chain (residues 153–406) disulfide-linked heterodimer, though the zymogen-to-enzyme transition is incomplete without cofactor binding.^[9] The active site in Factor VIIa features a catalytic triad composed of His193, Asp242, and Ser344, but this triad is stabilized and optimally positioned only upon binding to tissue factor, which induces allosteric changes to enhance catalytic efficiency.^[5] This conformational shift from a zymogen-like to an enzyme-like state underscores the protein's reliance on tissue factor for full activation.^[10]

Genetics

The F7 gene, which encodes coagulation factor VII, is located on the long arm of chromosome 13 at the q34 band (13q34).^[11] This gene spans approximately 12.8 kilobases (kb) and consists of nine exons interrupted by eight introns, producing a pre-pro-protein of 466 amino acids that undergoes processing to yield the mature 406-amino-acid factor VII polypeptide.^[12] The genomic organization reflects evolutionary duplication with the nearby F10 gene encoding factor X, both sharing structural similarities in their exon-intron boundaries.^[13] Transcription of the F7 gene is primarily liver-specific, driven by hepatocyte nuclear factor 4 alpha (HNF4α) and specificity protein 1 (Sp1) binding sites in the promoter region, ensuring high expression in hepatocytes where factor VII is synthesized and secreted.^[14] The promoter also contains responsive elements to hormones, including an estrogen response element that mediates repression by estrogen, leading to lower factor VII levels in response to hormonal changes, as well as sites influenced by insulin and androgens that modulate expression in metabolic contexts.^[15]^[16] Common polymorphisms in the F7 gene significantly influence plasma factor VII levels and associated thrombotic risk. The -323 A1/A2 (also denoted as -402 G/A) insertion/deletion variant in the promoter region alters transcriptional efficiency, with the A2 allele linked to higher factor VII antigen levels and increased risk of myocardial infarction in population studies.^[17] Similarly, the R353Q missense polymorphism (rs6025) in exon 8 reduces factor VII coagulant activity by approximately 20-30% in Q allele carriers due to impaired activation, correlating with a modest protective effect against coronary heart disease.^[18] These variants collectively explain up to one-third of the variability in circulating factor VII levels among healthy individuals.^[19] Rare mutations in F7 underlie hereditary factor VII deficiency, an autosomal recessive bleeding disorder with prevalence around 1 in 500,000. Missense mutations, such as Arg304Gln (FVII Padua) in exon 8, often result in cross-reacting material (CRM)-positive forms where dysfunctional protein is secreted but exhibits reduced activity due to impaired tissue factor binding or catalytic efficiency.^[20] Nonsense and frameshift mutations, conversely, typically lead to CRM-negative deficiency by triggering nonsense-mediated decay or producing truncated, non-secreted proteins, abolishing detectable antigen and causing severe reductions in factor VII levels (often <1% of normal).^[21] Over 200 such pathogenic variants have been cataloged, with missense changes predominating in CRM-reduced phenotypes where antigen levels are disproportionately low relative to residual activity. Recent genetic studies through 2025 have elucidated polygenic influences on factor VII activity levels beyond monogenic defects. Genome-wide association studies (GWAS) have identified additional loci, such as those near REEP3 and JAZF1-AS1, contributing to inter-individual variation in plasma factor VII, explaining further heritability after accounting for major polymorphisms.^[22] Exome-wide scans in large cohorts have pinpointed rare coding variants modulating factor VII coagulant activity, while investigations into activated factor VII-antithrombin complexes highlight polygenic predictors of levels in cardiovascular disease patients, underscoring the interplay of multiple genetic factors with environmental modulators.^[23]

Physiological Function

Role in Coagulation

Factor VII plays a pivotal role in initiating the extrinsic pathway of blood coagulation, which is triggered upon vascular injury when subendothelial tissue factor (TF) is exposed to circulating blood. In this process, Factor VII binds to TF on the damaged vessel surface, forming the TF-Factor VII complex that requires calcium ions for stabilization and activation.^[1] This complex rapidly converts a small fraction of plasma Factor VII to its active form, Factor VIIa, thereby kickstarting the coagulation cascade to prevent excessive blood loss.^[24] Once activated, Factor VIIa, in complex with TF, exerts key enzymatic actions by cleaving Factor X to Factor Xa and Factor IX to Factor IXa, which amplifies the downstream coagulation signals leading to thrombin generation and subsequent fibrin clot formation.^[1] These activations occur primarily on phospholipid surfaces provided by damaged cells or activated platelets, ensuring localized hemostasis. In healthy individuals, this mechanism maintains balanced coagulation, promoting thrombus formation at injury sites while avoiding widespread thrombosis through tight regulatory controls.^[25] Factor VII synthesis in the liver depends on vitamin K for post-translational gamma-carboxylation of glutamic acid residues, which is essential for its calcium-binding and functional activity.^[13] Circulating plasma concentrations of Factor VII are approximately 10 nM (or 500 ng/mL), with only 1-2% present as active Factor VIIa under normal conditions, reflecting its zymogen predominance to prevent premature clotting.^[26] The protein has a plasma half-life of about 4-6 hours, contributing to its sensitivity as an early marker of hepatic or vitamin K-related dysfunction.^[27] Factor VII activity is commonly assessed using prothrombin time (PT)-based clotting assays, which measure the extrinsic pathway's efficiency, while antigen levels are quantified via immunoassays such as enzyme-linked immunosorbent assay (ELISA) to distinguish between functional and total protein amounts.^[28]

Activation and Regulation

Factor VII, circulating primarily as an inactive zymogen, is activated through proteolytic cleavage at the Arg152-Ile153 peptide bond, yielding the two-chain enzyme Factor VIIa held together by a disulfide bridge. This cleavage is catalyzed by several proteases, including Factor Xa in the presence of calcium ions and phospholipids, thrombin, and Factor IXa on platelet surfaces.^[29]^[30] Additionally, autoactivation occurs within the tissue factor (TF)-VIIa complex on cell surfaces, where trace amounts of pre-existing VIIa (approximately 1% of total circulating Factor VII) initiate the process.^[31]^[13] The binding of Factor VIIa to tissue factor, often in association with phospholipids on damaged cell membranes, markedly enhances its catalytic efficiency toward substrates such as Factor X and Factor IX. This enhancement arises from allosteric changes that optimize the active site, increasing the specificity constant by up to $10^6-fold, as quantified by the ratio of catalytic rate constants:

\frac{(k_{\mathrm{cat}}/K_{\mathrm{m}})^{\mathrm{TF-VIIa}}}{(k_{\mathrm{cat}}/K_{\mathrm{m}})^{\mathrm{VIIa}}} \approx 10^6

where k_{\mathrm{cat}}/K_{\mathrm{m}} represents the second-order rate constant for substrate activation.^[1] Phospholipids, particularly phosphatidylserine exposed on activated platelets or endothelial cells, facilitate the assembly of the TF-VIIa complex by providing a membrane platform that concentrates the components and supports calcium-dependent interactions.^[32] Regulation of Factor VIIa activity prevents excessive coagulation through inhibitors and feedback mechanisms. Tissue factor pathway inhibitor (TFPI), a Kunitz-type serine protease inhibitor, quenches the TF-VIIa complex by first binding Factor Xa to form an intermediate, followed by formation of a stable quaternary complex (TF-VIIa-Xa-TFPI) that inhibits further downstream activation.^[33] The protein C anticoagulant pathway also modulates Factor VIIa via the endothelial protein C receptor (EPCR); Factor VIIa binds EPCR with affinity similar to protein C, potentially competing for the receptor and impairing EPCR-dependent activation of protein C to activated protein C (APC), which in turn inactivates cofactors Va and VIIIa.^[34] Positive feedback amplification occurs as thrombin, generated downstream, further cleaves zymogen Factor VII to VIIa, sustaining the response on phospholipid surfaces.^[35]^[36]

Clinical Relevance

Deficiency and Bleeding Disorders

Factor VII deficiency is a rare inherited bleeding disorder caused by mutations in the F7 gene, with a global prevalence estimated at 1 in 300,000 to 500,000 individuals.^[37]^[38] It follows an autosomal recessive inheritance pattern, meaning affected individuals are typically homozygous or compound heterozygous for pathogenic variants, while heterozygous carriers usually exhibit mild reductions in factor VII activity (often 50% or more) and are generally asymptomatic.^[38] Over 220 distinct F7 mutations have been identified, but genotype-phenotype correlations are inconsistent, as bleeding severity does not always align with residual factor VII levels due to influences like tissue factor expression and environmental factors.^[38]^[37] The condition is classified based on residual factor VII activity: severe deficiency involves levels below 1%, moderate ranges from 1% to 10%, and mild exceeds 10%.^[38] Clinical manifestations vary widely, even among those with similar activity levels; common presentations include mucocutaneous bleeding such as epistaxis and menorrhagia, while severe cases may involve life-threatening events like intracranial or gastrointestinal hemorrhage, often triggered by trauma, surgery, or spontaneously in infancy.^[37]^[38] For instance, neonates with severe deficiency may present with umbilical stump bleeding, and joint or muscle hemorrhages can occur in moderate to severe forms, though central nervous system bleeds remain a critical risk across severities.^[37] Diagnosis relies on laboratory findings of a prolonged prothrombin time (PT) with a normal activated partial thromboplastin time (aPTT), followed by confirmation via specific factor VII clotting activity assays or antigenic level measurements.^[38]^[37] Genetic testing can identify F7 variants to support inheritance patterns, particularly in families with consanguinity.^[38] Management poses challenges due to the disorder's rarity and phenotypic variability, which complicates predicting bleeding risk and dosing requirements for replacement therapies.^[39] On-demand treatments such as fresh frozen plasma or prothrombin complex concentrates carry risks of transfusion-related infections, volume overload, and allergic reactions, while prophylactic regimens are reserved for those with recurrent severe bleeds.^[38] A 2025 review emphasizes the need for personalized approaches to address this variability, highlighting ongoing efforts to refine prophylaxis based on individual bleeding history and activity levels rather than genotype alone.^[39]

Role in Thrombosis

Elevated levels of Factor VII antigen and activity have been associated with an increased risk of thrombotic events, including myocardial infarction, ischemic stroke, and venous thromboembolism. In the Northwick Park Heart Study, a prospective cohort involving middle-aged men, higher plasma Factor VII coagulant activity (FVIIc) was identified as an independent predictor of fatal coronary heart disease, with individuals in the highest quartile showing approximately a twofold increased risk compared to those in the lowest quartile. Similar associations have been observed for ischemic stroke, where genome-wide studies implicate Factor VII variants in disease susceptibility, and for venous thromboembolism, where Factor VII levels exceeding the 95th percentile were linked to a hazard ratio of 2.4 for incident events in population-based cohorts.^[40]^[41]^[42]^[43]^[44] The prothrombotic role of Factor VII in these conditions stems from enhanced formation of the tissue factor (TF)-Factor VIIa complex, which initiates excessive thrombin generation even on intact endothelium under hypercoagulable states. This complex activates factors IX and X, amplifying the coagulation cascade and leading to fibrin formation and platelet activation, thereby promoting thrombus development at sites of vascular injury or inflammation. In pathological scenarios, upregulated TF expression—driven by endothelial dysfunction or inflammatory cytokines—facilitates sustained TF-VIIa activity, resulting in unbalanced thrombin production that exceeds anticoagulant thresholds.^[45]^[13]^[46] Genetic polymorphisms in the Factor VII gene, such as the R353Q variant (rs6025), influence thrombotic risk by modulating plasma levels; the Q allele is associated with 20-30% lower Factor VII activity and a reduced odds ratio of 0.6-0.7 for myocardial infarction in case-control studies. Conversely, environmental factors like high-fat diets and obesity elevate Factor VII levels through mechanisms involving increased hepatic synthesis and postprandial activation, with obese individuals exhibiting up to 15-20% higher baseline activity compared to normal-weight controls. These factors interact with genetics, as certain haplotypes amplify obesity-related elevations in Factor VII.^[47]^[48]^[49]^[50] In disseminated intravascular coagulation (DIC) and sepsis-induced thrombosis, Factor VIIa plays a central role by mediating widespread TF-dependent coagulation, contributing to microvascular thrombi and organ dysfunction. During sepsis, endotoxin-induced TF upregulation on monocytes and endothelium forms TF-VIIa complexes that drive consumptive coagulopathy and excessive thrombin generation, with Factor VIIa-antithrombin complexes serving as biomarkers of severity and poor prognosis in affected patients. Recent cohort studies from 2023-2025 further link Factor VII variants and elevated Factor VIIa-antithrombin levels to adverse cardiovascular outcomes, including increased mortality in coronary artery disease and ischemic stroke risk in long-term follow-up, underscoring the variant's prognostic value in large populations.^[51]^[52]^[53]^[54]^[55]

Therapeutic Applications

Recombinant Factor VIIa

Recombinant factor VIIa (rFVIIa), also known as eptacog alfa for the original product, is produced through recombinant DNA technology using mammalian cell lines such as baby hamster kidney (BHK) cells to ensure proper post-translational modifications similar to the endogenous protein.^[56] This biotechnology approach avoids the risks associated with plasma-derived products, enabling large-scale manufacturing free from viral contaminants. Biosimilar versions, like AryoSeven, follow comparable recombinant processes, often validated against the reference product for bioequivalence in pharmacokinetics and pharmacodynamics.^[57] The U.S. Food and Drug Administration (FDA) first approved rFVIIa (NovoSeven, eptacog alfa) in 1999 for treating bleeding episodes and perioperative management in patients with hemophilia A or B who have developed inhibitors to factors VIII or IX.^[58] Subsequent expansions included approval for congenital factor VII deficiency in 2005 and for bleeding in Glanzmann thrombasthenia patients refractory to platelet transfusions in 2014.^[59]^[60] In 2020, the FDA approved eptacog beta (Sevenfact), a modified rFVIIa with enhanced stability, for controlling bleeding in hemophilia A or B patients with inhibitors aged 12 years and older.^[61] These approvals were based on clinical trials demonstrating hemostatic efficacy, with post-marketing surveillance confirming safety profiles.^[62] In clinical use, rFVIIa bypasses inhibitors by promoting tissue factor (TF)-independent thrombin generation on activated platelet surfaces, directly activating factor X to form a clot without relying on the inhibited upstream factors.^[63] This mechanism enhances local hemostasis at injury sites. Standard dosing for acute bleeding episodes in hemophilia patients with inhibitors is 90 mcg/kg administered intravenously every 2 hours until hemostasis, adjustable to every 3-6 hours for less severe cases or post-hemostasis maintenance.^[59] For congenital factor VII deficiency, lower doses of 15-30 mcg/kg every 4-6 hours are typical, while acquired hemophilia may require 70-90 mcg/kg every 2-3 hours.^[64] Administration is via bolus injection, with no need for reconstitution in some formulations like room-temperature stable versions.^[65] rFVIIa demonstrates high efficacy in surgical prophylaxis, achieving hemostasis in over 90% of procedures in hemophilia patients with inhibitors, as shown in registries and trials evaluating joint surgeries and dental extractions.^[66] In factor VII deficiency, it effectively controls spontaneous and trauma-induced bleeds, with response rates exceeding 95% in pediatric and adult cohorts.^[67] However, thrombotic adverse events, including arterial and venous thromboemboli, occur rarely (approximately 0.1-1% of treatments) but are more frequent in off-label uses or patients with cardiovascular risk factors.^[68]^[69] Monitoring for prothrombin time and factor VII activity is recommended, particularly in high-risk settings.^[59] As of 2025, the global market for rFVIIa products exceeds USD 1.2 billion annually, driven by increasing diagnoses of rare bleeding disorders and expanded access in emerging markets.^[70] Usage has grown steadily, with over 500,000 treatment episodes reported yearly in hemophilia registries, reflecting its role as a first-line bypassing agent. Cost-effectiveness analyses indicate that rFVIIa at 90 mcg/kg dosing yields lifetime ratios of approximately $6,300 per quality-adjusted life year gained compared to standard care in inhibitor patients, though higher doses increase costs without proportional efficacy gains.^[71] Biosimilars like AryoSeven have improved affordability, reducing treatment expenses by 20-30% in some regions.^[72]

Emerging Therapies

Gene therapy approaches for Factor VII (FVII) deficiency primarily utilize adeno-associated virus (AAV) vectors to target hepatic expression of the F7 gene, aiming to provide sustained coagulation factor production. Preclinical studies in FVII-deficient dogs have demonstrated long-term correction, with a single AAV8-mediated administration achieving greater than 10% of normal FVII levels for over three years, preventing spontaneous bleeding without toxicity.^[73] Similar results in murine models showed 100% survival post-challenge compared to 43% in untreated controls, highlighting the potential for durable hemostasis.^[74] Although no phase I trials specific to FVII deficiency have advanced by 2025, ongoing preclinical refinements, including hyperactive FVIIa variants, address challenges like vector immunogenicity and dose optimization.^[75] Modified recombinant FVIIa (rFVIIa) variants seek to extend half-life and reduce dosing frequency through protein engineering. Fusion of rFVIIa to human albumin via a flexible linker has extended the in vivo half-life six- to seven-fold in preclinical models, maintaining procoagulant activity while improving pharmacokinetics.^[76] Another approach involves fusion proteins linking rFVIIa to an Fc fragment or albumin, achieving a 3- to 4-fold half-life increase in preclinical studies, with reduced clearance and comparable hemostatic efficacy to standard rFVIIa. These innovations, still in early development as of 2025, target both congenital deficiencies and acquired coagulopathies, though immunogenicity remains a hurdle. Small molecule activators and tissue factor (TF) mimetics represent investigational strategies to enhance FVIIa activity in acquired deficiencies, bypassing the need for frequent infusions. Allosteric small molecules that stabilize the TF:FVIIa complex have shown promise in vitro by amplifying factor X activation, potentially aiding hemostasis in conditions like liver disease.^[77] Peptide-based TF mimetics, designed to mimic the cofactor's interaction with FVIIa, promote thrombin generation in preclinical assays without full TF exposure risks.^[78] These agents aim for oral or subcutaneous delivery, but clinical translation lags due to specificity concerns. CRISPR-based editing of F7 polymorphisms holds potential to mitigate thrombosis risk by modulating FVII levels, as validated in zebrafish models of venous thromboembolism where F7 knockdown reduced clot formation.^[79] Preclinical efforts target common variants like rs6046, which elevate FVIIa and associate with ischemic events, using Cas9 to introduce protective alleles. However, off-target effects and delivery challenges persist. By 2025, no human trials for F7 editing have begun, though broader CRISPR applications in hemophilia inform feasibility.^[80] Emerging therapies face challenges including immune responses to vectors or modified proteins and equitable access, yet 2025 progress includes phase I trials like SR604, an anti-activated protein C antibody for FVII deficiency and hemophilia, demonstrating prophylactic efficacy in murine models with a prolonged half-life.^[81] Off-label applications of rFVIIa variants in hemophilia trials report sustained hemostasis, with ongoing studies evaluating reduced dosing in inhibitor patients.^[82] These advancements underscore a shift toward rebalancing agents, though long-term safety data are needed.^[83]

Interactions

Molecular Interactions

Factor VIIa exhibits high-affinity binding to tissue factor (TF), a transmembrane glycoprotein exposed at sites of vascular injury, with a dissociation constant (Kd) of approximately 10 nM. This interaction primarily involves the γ-carboxyglutamic acid (Gla) domain and the first epidermal growth factor-like (EGF1) domain of Factor VIIa, which together facilitate specific recognition and docking to the extracellular domain of TF. The Gla domain coordinates calcium ions to promote initial membrane association, while the EGF1 domain contributes to the direct protein-protein interface, ensuring precise localization of the procoagulant complex.^[84]^[85]^[86]^[87] In addition to TF, activated Factor VII (VIIa) binds to the endothelial protein C receptor (EPCR) on vascular endothelial cells, with a Kd ranging from 30 to 150 nM. This interaction enhances VIIa proteolytic activity in an endothelium-specific manner and triggers anti-inflammatory signaling pathways, such as those mediated by protease-activated receptor 1 (PAR1) and β-arrestin-1, thereby modulating inflammatory responses at the vessel wall. Unlike TF binding, EPCR engagement occurs independently of phospholipids but complements the overall regulatory network of VIIa on intact endothelium.^[88]^[89] Membrane anchoring of Factor VII/VIIa is mediated by interactions with phospholipids, particularly exposed phosphatidylserine on activated or damaged cell surfaces, in a calcium-dependent manner. Calcium ions (Ca²⁺) bind to the Gla domain, inducing conformational changes that expose hydrophobic residues for insertion into the lipid bilayer, with optimal activity requiring millimolar concentrations of Ca²⁺. This anchoring stabilizes the VIIa-TF complex on the membrane surface, positioning it for efficient substrate engagement.^[90] The TF-VIIa complex serves as an enzyme for cleaving substrates Factor X (FX) and Factor IX (FIX), forming transient ternary complexes that drive downstream coagulation. Binding of FX or FIX induces allosteric changes in VIIa, including stabilization of the catalytic triad and repositioning of flexible loops, which enhance substrate affinity and catalytic efficiency by up to several orders of magnitude. These conformational shifts, particularly in the protease domain, are propagated from the TF interface and are essential for the ordered activation of FIX and FX.^[91]^[92]^[9] Recent structural studies utilizing cryo-electron microscopy (cryo-EM) in 2025 have elucidated the membrane-bound architecture of the TF-VIIa complex at near-atomic resolution (approximately 3-4 Å), incorporating nanodisc-embedded lipids to mimic physiological conditions. These structures highlight a novel allosteric mechanism where a serine-rich loop in TF undergoes a shift to allow access of the FX GLA domain to its binding location on the membrane-bound TF-FVIIa complex, promoting perpendicular orientation to the membrane and optimizing substrate access while explaining cellular decryption of TF procoagulant activity. Such insights refine understanding of the dynamic interfaces governing complex assembly and function.^[93]

Pharmacological Considerations

Vitamin K antagonists, such as warfarin, inhibit the γ-carboxylation of Factor VII in the liver by blocking the action of vitamin K epoxide reductase, resulting in the production of undercarboxylated, functionally inactive Factor VII that contributes to anticoagulation through prolongation of the prothrombin time (PT).^[94] This functional deficiency can be reversed by administering vitamin K, which restores γ-carboxylation, or by prothrombin complex concentrates (PCCs), which provide pre-formed carboxylated coagulation factors including Factor VII to rapidly normalize hemostasis in cases of bleeding or urgent reversal.^[95] Direct oral anticoagulants (DOACs) like rivaroxaban, a selective Factor Xa inhibitor, indirectly attenuate the activity of the Factor VIIa-tissue factor (TF) complex by blocking the downstream activation of prothrombin to thrombin, thereby reducing overall extrinsic pathway amplification without directly binding Factor VIIa.^[96] Unfractionated heparin and low-molecular-weight heparins primarily enhance antithrombin-mediated inhibition of thrombin and Factor Xa in the common pathway but also promote the release of tissue factor pathway inhibitor (TFPI), which directly inhibits the Factor VIIa-TF complex, further dampening extrinsic pathway initiation.^[97] Monitoring of Factor VII activity during anticoagulant therapy typically relies on PT and international normalized ratio (INR) assays, which are highly sensitive to reductions in Factor VII levels due to their central role in the extrinsic pathway, providing a practical measure of anticoagulation intensity with warfarin.^[98] For more precise quantification, chromogenic assays specifically measure Factor VII activity by tracking the rate of a chromogenic substrate cleavage dependent on Factor VIIa-TF complex formation, offering advantages in scenarios with interfering factors or for confirming isolated deficiencies.^[99] Recombinant Factor VIIa (rFVIIa), used for hemostatic support, carries warnings for increased thrombotic risk in patients with disseminated intravascular coagulation, advanced atherosclerosis, or other prothrombotic conditions, necessitating careful monitoring for signs of coagulation activation such as elevated D-dimer levels.^[59] Concomitant use of rFVIIa with procoagulant agents like activated PCCs is cautioned due to potential synergistic enhancement of thrombin generation, which may heighten the risk of arterial or venous thrombosis, and such combinations should be avoided unless benefits outweigh risks.^[59] According to the 2025 guidelines for direct oral anticoagulants, perioperative management in patients on DOACs involves interrupting therapy 24-48 hours preoperatively based on renal function and bleeding risk, without bridging anticoagulation, and resuming within 24-72 hours postoperatively while monitoring PT/INR to ensure safe hemostasis restoration.^[100] For warfarin-treated patients undergoing surgery, guidelines recommend holding doses 5 days prior to achieve an INR <1.5, with reversal using 4-factor PCC if urgent, prioritizing rapid normalization of Factor VII to minimize bleeding complications.^[101]

References

[1]
Biochemical, molecular and clinical aspects of coagulation factor VII ...
A comprehensive review on FVII is complex because of the wealth of information available both in the field of hemostasis and thrombosis (Figure 1). The main ...
[2]
The various assays for measuring activity states of factor VIIa in ...
Coagulation factor VII (FVII) is a single chain vitamin K dependent protein, with a molecular weight (MW) of about 50 kDa, synthesized in liver, present in ...
[3]
Structural Biology Of Factor VIIa/Tissue Factor Initiated Coagulation
Starting at the N-terminus, FVII contains a gamma-carboxyglutamic acid-rich domain (Gla domain, residues 1-38), a short hydrophobic segment (residues 39-45) ...
[4]
The Factor VII Zymogen Structure Reveals Reregistration of β ...
The Factor VII ... serine protease domain and initiates the cascade ... The Gla domain is followed by two epidermal growth factor-like (EGF) domains ...
[5]
Structure-function relationship of the interaction between tissue ...
Immediately C-terminal to the GLA domain is an aromatic stack and two epidermal growth factor (EGF) domains (EGF1 and EGF2). The aromatic stack connects the GLA ...
[6]
Coagulation Factor VII Gln100 3 Arg - Journal of Biological Chemistry
binant Q100RFVII—To rule out incomplete gamma-carboxylation of candidate Glu residues (residue numbers 6, 7, 14, 16, 19, 20, 25, 26,. 29, and 35) (10), purified ...
[7]
Posttranslational N-glycosylation takes place during the normal ...
Human FVII has two N-glycosylation sites (N145 and N322). Pulse-chase labeled intracellular FVII migrated as two bands corresponding to FVII with one and two N- ...
[8]
N-glycan-calnexin interactions in human factor VII secretion ... - NIH
Jun 8, 2019 · Factor VII (FVII) is a key serine protease in blood coagulation. N-glycosylation in FVII has been shown to be critical for protein secretion ...
[9]
Structure of human factor VIIa and its implications for the triggering ...
The active form of the enzyme, comprising a light chain (152 residues) and a heavy chain (254 residues) linked by a disulfide bond, is generated by the cleavage ...
[10]
The Factor VII Zymogen Structure Reveals Reregistration of β ...
An unprecedented 3 residue shift in registration between β strands B2 and A2 in the C-terminal β barrel and hydrogen bonds involving Glu154 provide new insight ...
[11]
Entry - *613878 - COAGULATION FACTOR VII; F7 - OMIM
▻ Mapping. The F7 gene maps to chromosome 13q34 (Millar et al., 2000). By dosage effects in 7 cases of abnormal chromosome 13, Gilgenkrantz et al. (1986) ...
[12]
Novel factor VII gene mutations in six families with hereditary ... - NIH
Aug 2, 2021 · The gene encoding FVII spans approximately 12.8 kb and consists of nine exons, with a precursor sequence containing a hydrophobic ...
[13]
Biochemical, molecular and clinical aspects of coagulation factor VII ...
Jan 7, 2021 · A comprehensive review on FVII is complex because of the wealth of information available both in the field of hemostasis and thrombosis (Figure ...Introduction · Congenital factor VII deficiency · Factor VII levels, F7 genotypes...
[14]
Liver-specific Expression of the Human Factor VII Gene - PubMed
Dec 19, 1995 · Two promoter elements that were essential for hepatocyte-specific transcription were identified. The first site, FVIIP1, located at bp -19 to +1 ...Missing: F7 hormones
[15]
Oestrogenic repression of human coagulation factor VII expression ...
) Liver-specific expression of the human factor VII gene. ... gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes.
[16]
Upregulation of the Coagulation Factor VII Gene during Glucose ...
We have previously demonstrated that F7 expression is modulated in response to insulin, via a promoter element that interacts with transcriptionally activating ...
[17]
Polymorphisms in the Factor VII Gene and the Risk of Myocardial ...
Sep 14, 2000 · High plasma levels of coagulation factor VII have been suggested to be predictors of death due to coronary artery disease.
[18]
Genetic Variation in Factor VII Associated with Variation in Plasma ...
Variation at codon 353 of F7 has been associated with variation in the plasma factor VII activity (FVIIc), with the 353Q allele associated with lower FVIIc and ...
[19]
Modulation of factor VII levels by intron 7 polymorphisms
Jun 1, 2000 · Previous studies have established that factor VII gene (F7) polymorphisms (5′F7 and R353Q) contribute about one-third of factor VII (FVII) level variation in ...
[20]
Characterization of mutations causing factor VII deficiency in 61 ...
The Arg304Gln, another CRMpositive mutation, was characterized by O'Brien et al. [17]. The intracellular content of FVII antigen in all three mutants was normal ...
[21]
Conformational Changes of Congenital FVII Variants with ... - NIH
In the first case, FVII activity and antigen are equally decreased giving origin to cases of “true” deficiency or cross reacting material (CRM) negative. In the ...
[22]
A genome-wide association study identifies new loci for factor VII ...
In this GWAS of circulating FVII levels, we identified the 6 previously known FVII loci as well as 2 new loci: REEP3 and JAZF1-AS1. In total, the 8 loci ...Missing: 2020-2025 | Show results with:2020-2025
[23]
Genetic determinants of activated factor VII-antithrombin plasma ...
Sep 9, 2025 · Genetic determinants of activated factor VII-antithrombin plasma levels and mortality in patients with coronary artery disease. Author links ...<|control11|><|separator|>
[24]
Physiology, Coagulation Pathways - StatPearls - NCBI Bookshelf
Jun 2, 2025 · Factor VIIa further activates factor X into factor Xa. At this stage, both the extrinsic and intrinsic pathways converge.
[25]
Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis ...
In vitro studies have shown that FVIIa binding to activated platelets is TF-independent and that FVIIa activates FIX, FX, and FXI in the presence of platelets.
[26]
F_7 - Overview: Coagulation Factor VII Activity Assay, Plasma
The factor VII assay is performed on the Instrumentation Laboratory ACL TOP using the prothrombin time (PT) method and a factor-deficient substrate. Patient ...
[27]
Activation of human factor VII by activated factors IX and X - PubMed
Without added phospholipid, activation of factor VII by both Xa and IXa was markedly slowed, and Xa was roughly 20 times more efficient than IXa. When both ...
[28]
Activation and control of factor VII by activated factor X and thrombin ...
Single chain Factor VII is rapidly hydrolyzed by Factor Xa in the presence of calcium ions and phospholipids, and by thrombin, to a two-chain form.Missing: loop | Show results with:loop
[29]
Tissue factor-dependent autoactivation of human blood coagulation ...
Kinetic analyses revealed that factor VII activation in the presence of relipidated tissue factor apoprotein can be defined by a second-order reaction ...
[30]
https://pubmed.ncbi.nlm.nih.gov/234427/
[31]
TISSUE FACTOR PATHWAY INHIBITOR: STRUCTURE-FUNCTION
Factor Xa-dependent inhibition of factor VIIa/tissue factor requires the Kunitz-1 domain of TFPI and involves the formation of a quaternary factor Xa-TFPI- ...
[32]
Factor VIIa binding to endothelial cell protein C receptor - PMC - NIH
Recent studies have shown that factor VIIa (FVIIa) binds specifically to endothelial protein C receptor (EPCR), a known cellular receptor for protein C and ...
[33]
Positive Feedback Loops for Factor V and Factor VII Activation ...
Positive feedback loops for fV and fVII activation render clotting sensitive to surface TF distribution. To validate the mathematical model prediction that the ...
[34]
Positive Feedback Loops for Factor V and Factor VII Activation ... - NIH
The role of positive feedback in the fVII activation of clotting disappeared, suggesting that fVII activation by fXa is important for the clotting process only ...
[35]
Rationale for the Potential Use of Recombinant Activated Factor VII ...
May 16, 2024 · By bypassing the intrinsic coagulation pathway locally, rFVIIa may accelerate the natural thrombin burst in a tissue-factor-independent manner.
[36]
Recombinant factor VIIa: new insights into the mechanism of action ...
Factor (F)VII is a vitamin-K-dependent glycoprotein characterized by the posttranslational γ-carboxylation of glutamic acid residues at conserved locations.
[37]
Factor VII Deficiency - Symptoms, Causes, Treatment | NORD
Factor VII deficiency is a rare genetic bleeding disorder characterized by a deficiency or reduced activity of clotting factor VII.Missing: prevalence | Show results with:prevalence
[38]
Factor VII Deficiency - Medscape Reference
May 30, 2024 · Factor VII (FVII) is a vitamin-K dependent clotting factor that is crucial in triggering blood coagulation.Missing: kDa | Show results with:kDa
[39]
Coagulation Factor VII Deficiency: A Review of the Clinical Implications and Approaches to Replacement Therapy and Prophylaxis
### Summary of Factor VII Deficiency from Cohan et al. (2025)
[40]
Coagulation factor VII and the risk of coronary heart disease in ...
Significant associations of FVIIc with increased coronary risk, however, have been found only in the Northwick Park Heart Study. Here we present the results ...
[41]
Coagulation Factor VII and the Risk of Coronary Heart Disease in ...
Significant associations of FVIIc with increased coronary risk, however, have been found only in the Northwick Park Heart Study. Here we present the results ...
[42]
Polymorphisms in the Factor VII Gene and the Risk of Myocardial ...
Sep 14, 2000 · The Northwick Park Heart Study investigators reported that a high plasma level of factor VII was a predictor of death due to coronary disease.
[43]
A genome-wide association study identifies new loci for factor VII ...
Feb 28, 2019 · THROMBOSIS AND HEMOSTASIS. A genome-wide association study identifies new loci for factor VII and implicates factor VII in ischemic stroke ...Thrombosis And Hemostasis · Methods · Results
[44]
Coagulation factors, inflammation markers, and venous ...
Factor VII levels above the 95th percentile, as compared with the lowest quartile, also conveyed a higher risk of venous thromboembolism (HR = 2.4; 95% CI: 1.2 ...
[45]
Thrombin generation by activated factor VII on platelet activated by ...
Tissue factor (TF) exposed after endothelial injury binds FVIIa to initiate thrombin generation (TG). In addition Factor VIIa on surface of platelets may cause ...
[46]
The Dynamics of Thrombin Formation | Arteriosclerosis, Thrombosis ...
During the initiation phase of the reaction, the factor VIIa-TF complex forms and generates small amounts (subpicomolar) of factor Xa and factor IXa.
[47]
Polymorphisms in the Coagulation Factor VII Gene and the Risk of ...
Jan 8, 1998 · Patients with the lowest level of factor VII clotting activity had a lower risk of myocardial infarction than those with the highest level (odds ...<|control11|><|separator|>
[48]
Polymorphism of R353Q (rs6046) in factor VII and the risk... - LWW
Sep 5, 2018 · The coagulation factor VII (FVII), as an initiator of the extrinsic coagulation pathway, has been found to be correlated to the MI risk.
[49]
Coagulation factor VII gene haplotypes, obesity‐related traits, and ...
Age, gender, diet and female hormones all strongly influence FVII levels or FVII activation. The distal promoter or Gln353 variant alleles may interact with ...
[50]
(PDF) Diet and blood coagulation factor VII - A key protein in arterial ...
Aug 6, 2025 · FVII:C and FVII protein concentration (FVII:Ag) are influenced by environmental factors such as diet and by genetic factors. We examined the ...
[51]
Disseminated Intravascular Coagulation (DIC) - Medscape Reference
Aug 23, 2022 · Factor VIIa has been implicated as the central mediator of intravascular coagulation in sepsis. Blocking the factor VIIa pathway in sepsis has ...Practice Essentials · Pathophysiology · Etiology
[52]
Role of tissue factor in disseminated intravascular coagulation
We examined plasma antigen levels of tissue factor (TF) in 95 cases of disseminated intravascular coagulation (DIC), to investigate the role of TF in DIC.
[53]
Disseminated intravascular coagulation and its immune mechanisms
Mar 31, 2022 · Blood coagulation is primarily triggered by the exposure of tissue factor (TF) to coagulation factor (F) VII/VIIa8 circulating in the plasma.Introduction · Pathogenesis Of Dic · Dic-Associated Pathologies<|separator|>
[54]
Genetic determinants of activated factor VII-antithrombin plasma ...
We investigated the genetic determinants of FVIIa-AT plasma levels by a candidate gene approach in a cohort of 610 subjects with (n = 478) or without (n = 132) ...
[55]
Antithrombin complexes in stable coronary artery disease: Impact on ...
May 29, 2025 · High FVIIa–AT complexes were associated with the risk of ischemic stroke/SE during long‐term follow‐up, highlighting the need for effective ...
[56]
Recombinant Activated Factor VII (rFVIIa) - ResearchGate
Aug 7, 2025 · Eptacog alfa (NovoSeven®) is a vitamin K-dependent recombinant Factor VIIa produced by genetic engineering from baby hamster kidney (BHK) ...
[57]
https://clinicaltrials.gov/study/NCT03935334
[58]
NovoSevenRT - FDA
Feb 21, 2018 · Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, ...
[59]
[PDF] NovoSeven RT - FDA
Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity before and after administration of NovoSeven RT.
[60]
FDA Approves NovoSeven® RT for the Treatment of Glanzmann's ...
Jul 7, 2014 · The FDA approved NovoSeven® RT for the treatment of GT based upon evidence collected from the global Glanzmann's Thrombasthenia Registry (GTR) ( ...
[61]
SEVENFACT - FDA
Jun 21, 2024 · Indication: For the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A ...
[62]
Current status and future prospects of activated recombinant ...
Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders.Missing: mammalian | Show results with:mammalian
[63]
Unifying the mechanism of recombinant FVIIa action: dose ... - NIH
The TF-dependent mechanism suggests that the hemostatic effect of rFVIIa is mediated by its binding to TF expressed on cell surfaces at the site of injury, ...
[64]
NovoSeven RT Dosage Guide - Drugs.com
Jun 30, 2025 · Acquired Hemophilia. 70-90 mcg/kg every 2-3 hours. Until hemostasis is achieved. Congenital Factor VII Deficiency. 15-30 mcg/kg every 4-6 hours.Missing: regimen | Show results with:regimen
[65]
NovoSeven® RT (coagulation Factor VIIa, recombinant)
NovoSeven RT is designed with your safety in mind. It's the only rFVIIa used for breakthrough bleeds in the Hemlibra pivotal clinical trials.Benefits · Considering Treatment · Living with factor VII deficiency? · Safety Profile
[66]
Efficacy and safety of recombinant factor VIIa in the prophylaxis of ...
Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor ...Missing: events | Show results with:events
[67]
AryoSeven RT (Coagulation factor VIIa, recombinant) safety...
Nov 4, 2022 · AryoSeven RT is safe and effective clinically and by laboratory data in stopping bleeding in patients older than 14 years with inherited FVII deficiency.Missing: mammalian | Show results with:mammalian
[68]
Safety of Recombinant Activated Factor VII in Randomized Clinical ...
Nov 4, 2010 · We found an increased risk of arterial thromboembolic events among patients who received off-label rFVIIa as compared with patients who received ...
[69]
Thromboembolic Adverse Events After Use of Recombinant Human ...
Jan 18, 2006 · Conclusions Most reported thromboembolic AEs followed the use of rFVIIa for unlabeled indications and occurred in arterial and venous systems, ...
[70]
Recombinant Human Coagulation VIIa Analysis 2025 and Forecasts ...
Rating 4.8 (1,980) May 6, 2025 · The size of the Coagulation Factor VIIa market was valued at USD 1230.2 million in 2023 and is projected to reach USD 1586.45 million by 2032, ...
[71]
Cost-effectiveness of recombinant activated factor VII in ... - PubMed
Results: Compared with standard care, treatment with rFVIIa 40 microg/kg, and 160 microg/kg results in total lifetime cost-effectiveness ratios of 6308 dollars/ ...
[72]
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated ...
Pharmacoeconomic analysis of recombinant factor VIIa vs. APCC in the treatment of minor-to moderate bleeds in hemophilia patients with inhibitors. Curr. Med ...
[73]
Sustained correction of FVII deficiency in dogs using AAV-mediated ...
Dec 23, 2015 · In these dogs, we determine the feasibility of a gene therapy approach using liver-directed, adeno-associated viral (AAV) serotype 8 vector ...Missing: paper | Show results with:paper
[74]
https://doi.org/10.1182/blood-2011-09-377630
[75]
Gene Therapy for Inherited Bleeding Disorders - PMC - NIH
Preclinical studies have also investigated gene transfer approaches for other rare inherited bleeding disorders, including factor VII deficiency, von Willebrand ...
[76]
Prolonged in-vivo half-life of factor VIIa by fusion to albumin - PubMed
Here we describe the generation of a recombinant FVIIa molecule with an extended half-life based on genetic fusion to human albumin.
[77]
Inhibitors of Factor VIIa/Tissue Factor | Arteriosclerosis, Thrombosis ...
Jun 28, 2007 · Some of these small molecule FVIIa/TF inhibitors have been tested in vivo and shown to be efficacious in preclinical models. The first reports ...
[78]
1WSS: Human Factor Viia-Tissue Factor in Complex with peptide ...
Nov 10, 2005 · Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two ...
[79]
Multi-ancestry GWAS for venous thromboembolism identifies novel ...
Jun 27, 2022 · We used CRISPR/Cas9 to knock down these potentially causal genes and measured time to occlusion after laser injury.
[80]
CRISPR and gene editing technologies for bleeding disorders - PMC
Oct 27, 2025 · A persistent challenge in gene therapy for hemophilia is the contrasting long-term outcomes observed between hemophilia A and B treatments.
[81]
Study Details | NCT06349473 - Clinical Trials
Participants with Hemophilia A or Hemophilia B or FVII deficiency will receive SR604 dose 7 as multiple SC injections every 4-weeks. Intervention/Treatment ...
[82]
Safety and efficacy of an anti–human APC antibody for prophylaxis ...
Sep 21, 2023 · SR604 exhibited prophylactic and therapeutic efficacy in the tail-bleeding and knee-injury models of hemophilia A and B mice expressing human ...Introduction · Materials and methods · Results · DiscussionMissing: VII | Show results with:VII
[83]
Coagulation Factor VII Deficiency: A Review of the Clinical ...
This review evaluates current therapeutic approaches, highlights emerging challenges in the management of FVII deficiency, and underscores the importance of ...
[84]
Factor VII binding to tissue factor in reconstituted phospholipid vesicles
With tissue factor incorporated into phosphatidylcholine vesicles, the Kd was 13.2 +/- 0.72 nM for factor VII and 4.54 +/- 1.37 nM for factor VIIa. Thus ...
[85]
Analysis of the factor VIIa binding site on human tissue ... - PubMed
Wild-type sTF binding to immobilized FVIIa has k(on) = 3.4 +/- 0.8 x 10(5) M-1 s-1 and k(off) = 2.1 +/- 0.1 x 10(-3) s-1 with a calculated KD of 6.3 +/- 1.2 nM ...Missing: VII | Show results with:VII
[86]
Factor VIIa's first epidermal growth factor-like domain's role in ...
The Kd for factor VII(IXegf1)a binding to tissue factor was 60-200-fold higher than that of factor VIIa depending on the assay employed. Only factor VII(IXegf1) ...
[87]
The roles of factor VII's structural domains in tissue factor binding
Factor VIIa binds to tissue factor in one of the initial steps of blood clotting. In order to determine the role of the various domains of the factor VII ...Missing: via | Show results with:via
[88]
Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1
May 24, 2018 · Our present data provide convincing evidence that FVIIa binding to EPCR elicits anti-inflammatory signaling via a PAR1- and β-arrestin-1 dependent pathway.Missing: VII | Show results with:VII
[89]
Factor VIIa suppresses inflammation and barrier disruption through ...
Coagulation protease, factor VIIa (FVIIa), binds to endothelial cell protein C receptor (EPCR) and induces anti-inflammatory and endothelial barrier protective ...
[90]
Tissue Factor/Factor VIIa Complex: Role of the Membrane Surface
This brief review will discuss new technologies we are bringing to bear to investigate protein-membrane interactions in blood clotting, with a special emphasis ...
[91]
How the tissue factor-VIIa complex keeps two substrates in the loop
The TF-VIIa complex uses a flexible serine loop to juggle its two major substrates: blood coagulation factors IX and X.
[92]
Evolutionary conservation of the allosteric activation of factor VIIa by ...
In mammals, the TF/FVIIa complex initiates coagulation by activating factors X (FX) and IX (FIX), leading to thrombin generation. Previous studies provided ...
[93]
Cryo-EM structure of the tissue factor/factor VIIa complex with a ...
Aug 14, 2025 · A novel, membrane-dependent allosteric mechanism controls FX GLA domain binding to TF/FVIIa and can explain decryption of cell-surface TF.
[94]
Prothrombin complex concentrates: an update - PMC - NIH
Vitamin K antagonists act through the inhibition of vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX and X and also of the endogenous ...
[95]
Prothrombin Complex Concentrates for Bleeding in the ... - NIH
Vitamin K antagonists, such as warfarin, effectively prevent essential post-translational gamma-carboxylation of the hepatically synthesized coagulation factors ...
[96]
Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates ...
Sep 27, 2023 · In the extrinsic coagulation pathway, the tissue factor (TF)/factor VIIa (FVIIa) complex promotes a cascade of proteolytic reactions ...
[97]
Studies on Tissue Factor Pathway Inhibitor Antigen Release ... - NIH
Oct 9, 2020 · Tissue factor pathway inhibitor antigen contributes to the anticoagulant effect of these heparins by inhibiting the TF-FVIIa complex. TFPI ...
[98]
International Normalized Ratio: Assessment, Monitoring, and ... - NCBI
Feb 14, 2025 · Intake of vitamin K antagonists: Warfarin inhibits the γ-carboxylation of vitamin K-dependent clotting factors, including factors II ( ...
[99]
Anticoagulation Monitoring for Perioperative Physicians - PMC
Chromogenic assays are thus less sensitive to low levels of other coagulation factors ... PT is most sensitive to low levels of Factor VII and Factor X. Since ...
[100]
2025 Guidelines for direct oral anticoagulants: a practical guidance ...
The optimal timing for anticoagulant resumption based on current available evidence is between 1 and 6 weeks depending on individual bleeding and ...